专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JPH08501566A 失效
公开(公告)号：JPH08501566A
公开(公告)日：1996-02-20
申请号：JP50854194
申请日：1993-09-15
申请人： BOEHRINGER INGELHEIM CA LTD
发明人： ANDERSON PAUL CATES , HALMOS TEDDY , JUNG GRACE LORENA , POUPART MARC-ANDRE , BRUNO SIMONEAU
IPC分类号： A61K31/16 , A61K31/165 , A61K31/40 , A61K31/4015 , A61K31/415 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4418 , A61P9/12 , A61P43/00 , C07C233/18 , C07C233/19 , C07C237/22 , C07D207/26 , C07D207/27 , C07D213/40 , C07D233/54 , C07D233/64 , C07D277/28 , C07D277/30 , C07D277/40 , C07D317/58 , C07D417/12

2. 发明申请

WO02052015A3 SELF-REPLICATING RNA MOLECULE FROM HEPATITIS C VIRUS 审中-公开
标题翻译：从HEPATITIS C病毒中自我更新RNA分子
公开(公告)号：WO02052015A3
公开(公告)日：2003-11-20
申请号：PCT/CA0101843
申请日：2001-12-20
申请人： BOEHRINGER INGELHEIM CA LTD , KUKOLJ GEORGE , PAUSE ARNIM
发明人： KUKOLJ GEORGE , PAUSE ARNIM
IPC分类号： G01N33/50 , C07K14/18 , C12N5/02 , C12N5/10 , C12N7/01 , C12N15/09 , C12N15/40 , C12N15/51 , C12N15/86 , C12Q1/02 , C12Q1/68 , G01N33/15 , C12N7/04 , C12N15/85 , C12Q1/70
CPC分类号： C07K14/005 , A61K2039/525 , C12N15/86 , C12N2770/24222 , C12N2770/24243 , C12N2840/206 , C12Q1/6897
摘要： A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5'-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G-->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.
摘要翻译：提供了独特的HCV RNA分子，其具有增强的建立细胞培养物复制的效率。 HCV非结构域内鉴定出新的适应性突变，提高了在细胞培养中建立持续复制的HCV RNA的效率。这种自复制多核苷酸分子与所有先前的报道相反，包含可以是A作为已经公开的G的替代物的5'-NTR，因此提供了包含自我复制型HCV RNA分子的现有系统的替代方案。 G - > A突变产生HCV RNA分子，其结合HCV非结构区域的突变，如G（2042）C / R突变，具有更高的转导和/或复制效率。当转染细胞系时，这些RNA分子可用于评价HCV复制的潜在抑制剂。

3. 发明申请

WO03014377A2 DIRECT BINDING ASSAY FOR IDENTIFYING INHIBITORS OF HCV POLYMERASE 审中-公开
标题翻译：用于鉴定HCV聚合酶抑制剂的直接结合测定
公开(公告)号：WO03014377A2
公开(公告)日：2003-02-20
申请号：PCT/CA0201214
申请日：2002-08-05
申请人： BOEHRINGER INGELHEIM CA LTD , KUKOLJ GEORGE , BEAULIEU PIERRE L , MCKERCHER GINETTE
发明人： KUKOLJ GEORGE , BEAULIEU PIERRE L , MCKERCHER GINETTE
IPC分类号： G01N33/50 , C12N15/09 , C12Q1/48 , G01N21/76 , G01N21/78 , G01N33/15 , G01N33/542 , C12Q1/00
CPC分类号： G01N33/542 , C12Q1/48 , G01N2333/18 , G01N2333/91245 , G01N2500/02 , G01N2500/04
摘要： A method for identifying compounds binding to HCV polymerase comprising the steps of:contacting said HCV polymerase or an analog thereof with a probe formula I:wherein A is O, S, N, NR1, or CR1, wherein R1 is defined herein;----- represents either a single or a double bond;R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein;B is NR3 or CR3, wherein R3 is defined herein;with the proviso that, when A is not N, then one of A or B is either CR1 or CR3, K is N or CR4, wherein R4 is defined herein;L is N or CR5, wherein R5 has the same definition as R4 defined above;M is N or CR7, wherein R7 has the same definition as R4 defined above;R5 is C(Y1)Z wherein Y1 is O or S; and Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het;or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S;R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle;or a salt thereof; where the probe comprises a detectable label attached to any suitable position, whereby said probe binds to an HCV polymerase or an analog thereof and is capable of being displaced by an inhibitor thereof.
摘要翻译：用于鉴定结合HCV聚合酶的化合物的方法，包括以下步骤：使所述HCV聚合酶或其类似物与式I的探针接触：其中A是O，S，N，NR1或CR1，其中R 1在本文中定义; ---表示单键或双键; R2选自：H，卤素，R21，OR21，SR21，COOR21，SO2N（R22）2，N（R22）2，CON（R22）2，NR22C ）R 22或NR 22 C（O）NR 22，其中R 21和每个R 22如本文所定义; B是NR 3或CR 3，其中R 3在本文中定义;条件是当A不为N时，A或B中的一个为CR1或 CR 3，K是N或CR 4，其中R 4在本文中定义; L是N或CR 5，其中R5具有与上述定义的R4相同的定义; M是N或CR7，其中R7具有与上述定义的R4相同的定义; R5是 C（Y1）Z，其中Y1是O或S; 并且Z是N（R6a）R6或OR6，其中R6a是H或烷基或NR61R62，其中R61和R62在本文中定义; 并且R 6是H，烷基，环烷基，烯基，Het，烷基 - 芳基，烷基-Het;或R 6是其中R 7和R 8和Q如本文所定义; Y2是O或S; R9是H，（C1-6烷基），（C3-7）环烷基或（C1-6）烷基 - （C3-7）环烷基，芳基，Het，（C1-6）烷基 - 芳基或（C 1-6）烷基-Het，它们全部被R 90取代; 或R 9与R 7或R 8中的任一个共价键合以形成5-或6-元杂环;或其盐; 其中所述探针包含连接到任何合适位置的可检测标记，由此所述探针结合HCV聚合酶或其类似物，并且能够被其抑制剂置换。

5. 发明申请

WO0009543A3 HEPATITIS C INHIBITOR TRI-PEPTIDES 审中-公开
标题翻译： HEPATITIS C抑制剂TRI-PEPTIDES
公开(公告)号：WO0009543A3
公开(公告)日：2000-05-25
申请号：PCT/CA9900736
申请日：1999-08-09
申请人： BOEHRINGER INGELHEIM CA LTD , LLINAS BRUNET MONTSE , BAILEY MURRAY D , CAMERON DALE , FAUCHER ANNE MARIE , GHIRO ELISE , GOUDREAU NATHALIE , HALMOS TEDDY , POUPART MARC ANDRE , RANCOURT JEAN , TSANTRIZOS YOULA S , WERNIC DOMINIK M , SIMONEAU BRUNO
发明人： LLINAS-BRUNET MONTSE , BAILEY MURRAY D , CAMERON DALE , FAUCHER ANNE-MARIE , GHIRO ELISE , GOUDREAU NATHALIE , HALMOS TEDDY , POUPART MARC-ANDRE , RANCOURT JEAN , TSANTRIZOS YOULA S , WERNIC DOMINIK M , SIMONEAU BRUNO
IPC分类号： C12N15/09 , A61K31/13 , A61K31/7056 , A61K38/00 , A61K38/06 , A61K38/21 , A61P1/16 , A61P31/12 , A61P31/14 , C07C229/48 , C07K1/06 , C07K5/08 , C07K5/083 , C07K5/087 , C12N9/50 , C12N9/99 , C12P21/02 , C12P41/00
CPC分类号： C12P13/02 , A61K38/21 , A61K45/06 , C07D207/16 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C12P41/005 , A61K2300/00
摘要： Racemates, diastereoisomers and optical isomers of a compound of formula (I) wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R4-C(O)-; a carboxyl of formula R4-O-C(O)-; an amide of formula R4-N(R5)-C(O)-; a thioamide of formula R4-N(R5)-C(S)-;or a sulfonyl of formula R4-SO2; R5 is H or C1-6 alkyl; and Y is H or C1-6 alkyl; R is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl; R2 is CH2-R20, NH-R20, O-R20or S-R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21, or R20 is a C6 or C10 aryl or C7-14 aralkyl optionally substituted, or R20 is Het or (lower alkyl)-Het, both optionally substituted, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C6 or C10 aryl, C7-14 aralkyl or Het, said aryl, aralkyl or Het being optionally substituted; and R is H; C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, or C2-6 alkynyl, all optionally substituted with halogen; or a pharmaceutically acceptable salt or ester thereof.
摘要翻译：式（I）化合物的外消旋物，非对映异构体和光学异构体，其中B是H，C6或C10芳基，C7-16芳烷基; Het或（低级烷基）-Het，其全部任选被C 1-6烷基取代; C 1-6烷氧基; C 1-6烷酰基; 羟基; 羟; 光环; 卤代; 硝基; 氰基; 氰; 任选被C 1-6烷基取代的氨基; 酰胺基; 或（低级烷基）酰胺; 或B是式R4-C（O） - 的酰基衍生物; 式R4-O-C（O） - 的羧基; 式R 4 -N（R 5）-C（O） - 的酰胺; 式R 4 -N（R 5）-C（S） - 的硫代酰胺;或式R4-SO2的磺酰基; R5是H或C1-6烷基; Y为H或C 1-6烷基; R 3是C 1-8烷基，C 3-7环烷基或C 4-10烷基环烷基，其全部被羟基，C 1-6烷氧基，C 1-6硫代烷基，酰氨基，（低级烷基）酰氨基，C 6或C 10芳基取代，或C7-16芳烷基; R2是CH2-R20，NH-R20，O-R20或S-R20，其中R20是饱和或不饱和的C3-7环烷基或C4-10（烷基环烷基），它们全部是任选的一，二或三取代 R 21或R 20为任选取代的C 6或C 10芳基或C 7-14芳烷基，或R 20为Het或（低级烷基）-Het，均为任选取代的Het或（低级烷基）-Het; 羧基; 羧基（低级烷基）; C6或C10芳基，C7-14芳烷基或Het，所述芳基，芳烷基或Het任选被取代; 并且R 1是H; C 1-6烷基，C 3-7环烷基，C 2-6烯基或C 2-6炔基，全部被卤素取代; 或其药学上可接受的盐或酯。

6. 发明申请

WO9907734A3 HEPATITIS C INHIBITOR PEPTIDE ANALOGUES 审中-公开
标题翻译： HEPATITIS C抑制肽类似物
公开(公告)号：WO9907734A3
公开(公告)日：1999-05-20
申请号：PCT/CA9800764
申请日：1998-08-10
申请人： BOEHRINGER INGELHEIM CA LTD , LLINAS BRUNET MONTSE , BAILEY MURRAY DOUGLAS , HALMOS TEDDY , POUPART MARC ANDRE , TSANTRIZOS YOULA
发明人： LLINAS-BRUNET MONTSE , BAILEY MURRAY DOUGLAS , HALMOS TEDDY , POUPART MARC-ANDRE , TSANTRIZOS YOULA
IPC分类号： A61K45/00 , A61K31/13 , A61K31/7056 , A61K38/00 , A61K38/21 , A61P31/14 , C07K7/06 , C07K14/18 , A61K38/04 , A61K38/16 , C07K5/093 , C07K5/107
CPC分类号： C07K7/06 , A61K38/00 , C07K14/005 , C12N2770/24222
摘要： Compound of formula (I) active against the Hepatitis C virus, wherein B is an acyl derivative; a is 0 or 1; R6, when present, is carboxy(lower)alkyl; b is 0 or 1; R5, when present, is C1-6 alkyl, or carboxy(lower)alkyl; Y is H or C1-6 alkyl; R4 is C1-10 alkyl; R3 is C1-10 alkyl; W is -NH-CH(R2)-C(O)-, wherein R2 is C1-6 alkyl; C6 or C10 aryl; C7-16 aralkyl; or carboxy(lower)alkyl; or W is a proline derivative; Q is a group of the formula -Z(R1)-C(O)-R13, wherein Z is CH or N; R1 is C1-6 alkyl or C1-6 alkenyl both optionally substituted with thio or halo; and R13 is an activated carbonyl substituent, or Q is a phosphonate group of the formula -CH(R1)-P(O)R15R16 wherein R15 and R16 are independently C6-20 aryloxy; and R1 is as defined above.
摘要翻译：对丙型肝炎病毒有活性的式（I）化合物，其中B为酰基衍生物; a是0或1; 当存在时，R 6为羧基（低级）烷基; b为0或1; 当存在时，R 5为C 1-6烷基或羧基（低级）烷基; Y是H或C 1-6烷基; R4是C1-10烷基; R3是C1-10烷基; W是-NH-CH（R 2）-C（O） - ，其中R 2是C 1-6烷基; C6或C10芳基; C7-16芳烷基; 或羧基（低级）烷基; 或W是脯氨酸衍生物; Q是式-Z（R1）-C（O）-R13的基团，其中Z是CH或N; R 1是任选被硫或卤代取代的C 1-6烷基或C 1-6链烯基; 并且R 13是活化的羰基取代基，或Q是式-CH（R 1）-P（O）R 15 R 16的膦酸酯基团，其中R 15和R 16独立地是C 6-20芳氧基; 并且R 1如上所定义。

7. 发明申请

WO03012127A3 ASSAY FOR IDENTIFYING INHIBITORS OF HIV RT DIMERIZATION 审中-公开
标题翻译：分析鉴定HIV逆转录酶抑制剂的抑制剂
公开(公告)号：WO03012127A3
公开(公告)日：2003-10-16
申请号：PCT/CA0201162
申请日：2002-07-26
申请人： BOEHRINGER INGELHEIM CA LTD , SLUIS-CREMER NICOLAS , PARNIAK MICHAEL , PELLETIER ALEX
发明人： SLUIS-CREMER NICOLAS , PARNIAK MICHAEL , PELLETIER ALEX
IPC分类号： G01N33/53 , A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , C12N15/09 , C12P19/34 , C12P21/06 , C12Q1/48 , C12Q1/68 , C12Q1/70 , G01N21/78 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/48 , G01N2333/9125 , G01N2500/02
摘要： A method for measuring heterodimerization of HIV RT, which comprises the steps of:a) providing a first solution comprising p66 subunit homodimers in the presence of a dissociation agent; b) contacting the first solution with p51 RT subunits and incubating in the presence of a reassociation buffer to allow association of a complex of p66/p51 RT subunits, wherein one of the subunits comprises an affinity tag and the other of the subunits comprises a detectable label; c) contacting the incubate of step b) with an affinity medium under conditions that enable the p66/p51 complex to bind to the affinity medium; and d) determining the amount of complex formed by measuring the level of detectable label bound to the affinity medium (or by measuring the reconstituted RT polymerase activity). Steps a) to d) can be carried out in the presence or absence of a test compound followed by e) comparing the test compound sample to a control sample lacking the compound, whereby modulated p66/p51 complex formation in the test compound sample is indicative of the ability of the compound to modulate, inhibit or enhance heterodimerization.The method can be used to screen for inhibitors of HIV RT dimerization.
摘要翻译：用于测量HIV RT的异源二聚化的方法，其包括以下步骤：a）在解离剂存在下提供包含p66亚基同源二聚体的第一溶液; b）使第一溶液与p51RT亚基接触，并在重新结合缓冲液存在下温育以允许p66 / p51RT亚基复合物的缔合，其中一个亚基包含亲和标签并且另一个亚基包含可检测的标签; c）在能够使p66 / p51复合物结合亲和介质的条件下，将步骤b）的孵育物与亲和介质接触; 和d）通过测量与亲和介质结合的可检测标记的水平（或通过测量重建的RT聚合酶活性）来确定形成的复合物的量。可以在存在或不存在测试化合物的情况下进行步骤a）至d），然后e）将测试化合物样品与缺乏该化合物的对照样品进行比较，由此在测试化合物样品中调节的p66 / p51复合物形成是指示性的该化合物调节，抑制或增强异二聚化的能力。该方法可用于筛选HIV RT二聚化的抑制剂。

8. 发明申请

WO03010140A3 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE 审中-公开
标题翻译：具有异构结构的丙型肝炎病毒聚合酶抑制剂
公开(公告)号：WO03010140A3
公开(公告)日：2003-07-10
申请号：PCT/CA0201127
申请日：2002-07-18
申请人： BOEHRINGER INGELHEIM CA LTD , BEAULIEU PIERRE LOUIS , FAZAL GULREZ , KUKOLJ GEORGE , JOLICOEUR ERIC , GILLARD JAMES , POUPART MARC-ANDRE , RANCOURT JEAN
发明人： BEAULIEU PIERRE LOUIS , FAZAL GULREZ , KUKOLJ GEORGE , JOLICOEUR ERIC , GILLARD JAMES , POUPART MARC-ANDRE , RANCOURT JEAN
IPC分类号： A61K31/13 , A61K31/381 , A61K31/404 , A61K31/405 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/428 , A61K31/437 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/7052 , A61K38/21 , A61K45/00 , A61P31/12 , A61P31/14 , A61P37/02 , A61P43/00 , C07D20060101 , C07D209/08 , C07D209/14 , C07D209/20 , C07D209/30 , C07D209/42 , C07D333/62 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/02 , C07D471/04 , C07D491/02 , C07D498/02 , C07H19/056 , A61K31/4402
CPC分类号： C07D333/62 , C07D209/08 , C07D209/30 , C07D209/42 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D471/04
摘要： An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula (I) wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond;R2 is selected from: H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22 wherein R21 and each R22 is defined herein;B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein;K is N or CR4, wherein R4 is defined herein;L is N or CR5, wherein R5 has the same definition as R4 defined above;M is N or CR7, wherein R7 has the same definition as R4 defined above;Y1 is O or S;Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein;a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
摘要翻译：由式（I）表示的化合物的异构体，对映异构体，非对映异构体或互变异构体，其中：A是O，S，NR 1或CR 1，其中R 1在本文中定义; 代表单键或双键; R2选自：H，卤素，R21，OR21，SR21，COOR21，SO2N（R22）2，N（R22）2，CON（R22）2，NR22C（O） NR 22 C（O）NR 22，其中R 21和每个R 22如本文所定义; B是NR 3或CR 3，条件是A或B中的一个是CR 1或CR 3，其中R 3在本文中定义; K是N或CR 4，其中R 4是 L是N或CR5，其中R5具有与上述定义的R4相同的定义; M是N或CR7，其中R7具有与上述定义的R4相同的定义; Y1是O或S; Z是N（R6a）R6 或OR 6，其中R 6a是H或烷基或NR 61 R 62，其中R 61和R 62在本文中定义;其盐或其衍生物，作为HCV NS5B聚合酶的抑制剂。

9. 发明申请

WO03010141A3 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE 审中-公开
标题翻译：具有异构结构的丙型肝炎病毒聚合酶抑制剂
公开(公告)号：WO03010141A3
公开(公告)日：2003-05-30
申请号：PCT/CA0201128
申请日：2002-07-18
申请人： BOEHRINGER INGELHEIM CA LTD , BEAULIEU PIERRE LOUIS , FAZAL GULREZ , GOULET SYLVIE , KUKOLJ GEORGE , POIRIER MARTIN , TSANTRIZOS YOULA S , JOLICOEUR ERIC , GILLARD JAMES , POUPART MARC-ANDRE , RANCOURT JEAN
发明人： BEAULIEU PIERRE LOUIS , FAZAL GULREZ , GOULET SYLVIE , KUKOLJ GEORGE , POIRIER MARTIN , TSANTRIZOS YOULA S , JOLICOEUR ERIC , GILLARD JAMES , POUPART MARC-ANDRE , RANCOURT JEAN
IPC分类号： A61K31/13 , A61K31/381 , A61K31/404 , A61K31/405 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/428 , A61K31/437 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/7052 , A61K38/21 , A61K45/00 , A61P31/12 , A61P31/14 , A61P37/02 , A61P43/00 , C07D20060101 , C07D209/08 , C07D209/14 , C07D209/20 , C07D209/30 , C07D209/42 , C07D333/62 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/02 , C07D471/04 , C07D491/02 , C07D498/02 , C07H19/056 , C07D403/12
CPC分类号： C07D333/62 , C07D209/08 , C07D209/30 , C07D209/42 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D471/04
摘要： An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR , or CR , wherein R is defined herein; represents either a single or a double bond;R is selected from: H, halogen, R , OR , SR , COOR ,SO2N(R )2, N(R )2, , CON(R )2,NR C(O)R or NR C(O)NR wherein R and each R is defined herein; B is NR or CR , with the proviso that one of A or B is either CR or CR , wherein R is defined herein; K is N or CR , wherein R is defined herein; L is N or CR , wherein R has the same definition as R ; M is N or CR , wherein R has the same definition as R ; Y is O or S; Z is N(R )R or OR , wherein R is H or alkyl or NR R wherein R and R are defined herein; and R is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het;or R is wherein R and R and Q are as defined herein; Y is O or S; R is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R ; or R is covalently bonded to either of R or R to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
摘要翻译：由式I表示的化合物的异构体，对映异构体，非对映异构体或互变异构体：其中：A是O，S，NR 1或CR 1，其中R 1在本文中定义; 表示单键或双键; R 2选自：H，卤素，R 21，OR 21，SR 21，COOR 21，SO 2 N（R 22）2， N（R 22）2，CON（R 22）2，NR 22 C（O）R 22或NR 22 C（O）NR 22其中R 21和每个R 22在本文中定义; B是NR 3或CR 3，条件是A或B中的一个是CR 1或CR 3，其中R 3在本文中定义; K是N或CR 4，其中R 4在本文中定义; L是N或CR 5，其中R 5具有与R 4相同的定义; M是N或CR 7，其中R 7具有与R 4相同的定义; Y 1是O或S; Z是N（R 6a）R 6或OR 6，其中R 6a是H或烷基或NR 61 R 62，其中R 61和R 62定义在本文中 ; 且R 6为H，烷基，环烷基，烯基，Het，烷基 - 芳基，烷基-Het;或R 6为其中R 7和R 8和Q如本文所定义; Y 2为O或S; R 9是H，（C 1-6烷基），（C 3-7）环烷基或（C 1-6）烷基 - （C 3-7）环烷基，芳基，Het，（C 1-6）烷基 - 芳基或（C 1 -6）烷基-Het，它们全部被R 90取代; 或R 9与R 7或R 8中的任一个共价键合以形成5-或6-元杂环; 其盐或其衍生物，作为HCV NS5B聚合酶的抑制剂。

10. 发明申请

WO0032226B1 XENOGRAFT ANIMAL MODEL FOR THE INDUCTION OF PAPILLOMAS, THE PRODUCTION OF PAPILLOMAVIRUS AND THE PROPAGATION THEREOF 审中-公开
标题翻译：刺激动物动物模型，生产斑马鱼及其传播
公开(公告)号：WO0032226B1
公开(公告)日：2001-01-11
申请号：PCT/CA9901153
申请日：1999-11-30
申请人： BOEHRINGER INGELHEIM CA LTD , DUAN JIANMIN
发明人： DUAN JIANMIN
IPC分类号： A01K67/027 , A61K39/12 , A61P31/12 , C12N7/02 , A61K49/00
CPC分类号： A01K67/0271 , A01K2267/0337 , C12N2710/20051
摘要： The present invention relates to an animal model for inducing, producing and propagating papillomavirus and for evaluating candidate therapeutic agents against papillomavirus. The animal model comprises an immuno-deficient animal recipient onto which is grafted excised skin from a xenogeneic donor animal that is free from apparent PV infection and is a host to a host-specific papillomavirus. The grafted skin on the recipient animal supports the propagation of its host-specific papillomavirus. The invention particularly relates to, a recipient animal being a xenograft animal, capable of being a host for propagating a host specific papillomavirus and a means for producing infectious papillomavirus suspension. The invention further relates to the use of the xenograft animal model for evaluating potential therapeutic agents against papillomavirus infection.
摘要翻译：本发明涉及用于诱导，产生和繁殖乳头瘤病毒的动物模型，并用于评估针对乳头瘤病毒的候选治疗剂。动物模型包含免疫缺陷的动物接受者，其中移植切除的皮肤来自不存在明显的PV感染的异种供体动物，并且是宿主特异性乳头瘤病毒的宿主。受体动物的嫁接皮肤支持其宿主特异性乳头瘤病毒的繁殖。本发明特别涉及能够作为繁殖宿主特异性乳头瘤病毒的宿主的异种移植动物的受体动物和用于产生感染性乳头瘤病毒悬浮液的手段。本发明还涉及异种移植物动物模型用于评估针对乳头瘤病毒感染的潜在治疗剂的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式